ProQR Therapeutics N.V.Company Review & Valuation

PRQR
Nasdaq
Latest Price
3.69USD
Market Capitalization
183.56mUSD

About ProQR Therapeutics N.V.

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleShow moreotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome. It is also developing QRX-1011, a single-stranded oligonucleotide for Stargards disease; QRX-704, an oligonucleotide for the treatment of Huntington's disease; and QRX-504 to treat Fuchs' endothelial corneal dystrophy type 3, as well as AT-010, a program for hereditary cerebral hemorrhage with amyloidosis of the Dutch type. The company has a research collaboration agreement with Galapagos N.V. to apply Axiomer, a RNA Editing Technology Platform for various fibrosis targets; and a collaboration agreement with EB Research Partnership and EB Medical Research Foundation to develop QR-313 for patients with dystrophic epidermolysis bullosa. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.Show less

Industry
Biotechnology
HQ Location
Leiden, the Netherlands

Stock Price

Price data not available for ProQR Therapeutics N.V..

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

Basilea Pharmaceutica
KalVista Pharmaceuticals
Regenxbio
Celgene

back to top